featured
Tisagenlecleucel Is Not Superior to Salvage Therapy in B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
N. Engl. J. Med 2021 Dec 14;[EPub Ahead of Print], MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, A Sureda, R Greil, C Thieblemont, F Morschhauser, M Janz, I Flinn, W Rabitsch, YL Kwong, MJ Kersten, MC Minnema, H Holte, EHL Chan, J Martinez-Lopez, AMS Müller, RT Maziarz, JP McGuirk, E Bachy, S Le Gouill, M Dreyling, H Harigae, D Bond, C Andreadis, P McSweeney, M Kharfan-Dabaja, S Newsome, E Degtyarev, R Awasthi, C Del Corral, G Andreola, A Masood, SJ Schuster, U Jäger, P Borchmann, JR WestinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.